TLC to Present at Berenberg Pain Seminar
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – November 12, 2019 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the Company’s management team will be presenting its product candidates in pain management –TLC599 for osteoarthritis knee pain and TLC590 for postsurgical pain – at the Berenberg Pain Seminar on Wednesday, November 13, 2019 at the Berenberg offices in New York.
TLC599 is a non-opioid, proprietary BioSeizer® sustained release formulation of dexamethasone intended to manage osteoarthritis pain for up to six months; TLC590 is a non-opioid, BioSeizer® formulation of ropivacaine with the potential to manage postsurgical pain for four to seven days with a single dose. TLC599 and TLC590, which are currently in their Phase III and Phase II clinical trials, respectively, have the potential to deter or avoid the use of addictive opioids.
The seminar will include panel discussions and presentations featuring influential figures and experts in pain management. George Yeh, President of TLC, will be making the company introduction alongside peers in the pain management landscape, including Arena Pharmaceuticals, Flexion Therapeutics, Pacira BioSciences and Recro Pharma.
A copy of the TLC presentation can be accessed under “News and Events” in the Investors section of TLC’s website at www.tlcbio.com.
TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology.